PhaseBio Ends Pemziviptadil Trial for PAH, Citing COVID-19 Impact

PhaseBio Ends Pemziviptadil Trial for PAH, Citing COVID-19 Impact

314808

PhaseBio Ends Pemziviptadil Trial for PAH, Citing COVID-19 Impact

PhaseBio Pharmaceuticals has voluntarily ended the Phase 2b trial testing its investigational pulmonary arterial hypertension (PAH) therapy pemziviptadil (PB1046), due to the impact of the COVID-19 pandemic on medicine manufacturing, associated supply, and enrollment rates. The company said it would conduct an analysis of the trial’s results and, if positive, may continue the program in a future study with improved product presentation and a simplified dosing regimen. “With the continued impact of the COVID-19 pandemic…

You must be logged in to read/download the full post.